1. Changping Deng, Jiacheng Ma, Yuping Liu, Xikui Tong, Lei Wang, Jiayi Dong, Ping Shi, Meiyan Wang, Wenyun Zheng*, Xingyuan Ma*. Targeting intracellular cancer proteins with tumor-microenvironment-responsive bispecific nanobody-PROTACs for enhanced therapeutic efficacy. MedComm. 2025 ;6(2): e70068.

2. Yunhui Fu, Yiwen Zhou, Yiying Chen, Zhedan Zhang, Chen Zhang, Changping Deng, Xikui Tong, Wenyun Zheng*，Meiyan Wang* and Xingyuan M*. Development of ZmT-PEG hydrogels through Michael addition reaction and protein self-assembly for 3D cell culture.Biomaterial Science, 2024, 12, 5803-5811   

3. Lei Wang, Jiayi Dong, Chenglu Wu, Chengyue Yan, Chong Bi, Chengnan Xu, Yilin Wu, WenyunZheng* and Xingyuan Ma*. Development of a synthetic library of humanized nanobodies for targeted IL-6 inhibition.Frontiers in Bioengineering and Biotechnology, 2024,12: 1440150.

4. Changping Deng, Shihui Li, Yuping Liu, Wen Bao, Chengnan Xu, Wenyun Zheng*, Meiyan Wang, Xingyuan Ma*. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras ontogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clinical and Translational Medicine. 2023, 13(8): e1382.   

5. Hui Miao, Chang Liu, Hao Ouyang, Peiwen Zhang, Yuping Liu, Chen Zhang, Changping Deng, Yunhui Fu, Jinping Niu, Wenyun Zheng*, Fang You, Yi Yang* and Xingyuan Ma*. A nanobody-based molecular toolkit for ubiquitin-proteasome system explores the main role of survivin subcellular localization. Frontiers in Bioengineering and Biotechnology, 2023, 10.3389  

6. Fabiao Hu, Changping Deng, Yiwen Zhou, Yuping Liu, Tong Zhang, Peiwen Zhang, Zhangting Zhao, Hui Miao, Wenyun Zheng*, Wenliang Zhang, Meiyan Wang*, Xingyuan Ma*, Multistage targeting and dual inhibiting strategies based on bioengineered tumor matrix microenvironment-mediated protein nanocages for enhancing cancer biotherapy,Bioengineering & Translational Medicine, 2022; 7(2): e10290.

7. Changping Deng, Fabiao Hu, Zhangting Zhao, Yiwen Zhou, Yuping Liu, Tong Zhang, Shihui Li, Wenyun Zheng*, Wenliang Zhang, Tianwen Wang*, Xingyuan Ma*. The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-glycoprotein in Cancer Multi-drug Resistance, Frontiers in Cell and Developmental Biology, 2021,10.3389.

8. Wei Guo, Xingyuan Ma, Yunhui Fu, Chang Liu, Qiuli Liu, Fabiao Hu, Hui Miao, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang* and Wenyun Zheng*. Discovering and characterizing of survivin dominant negative mutants with stronger pro-apoptotic activity on cancer cells and CSCs. Frontiers in Oncology. 2021, 11:635233.

9. Jifan Nie, Xingyuan Ma, Fabiao Hu, Hui Miao, Peiwen Zhang, Myong Hun Han, Fang You, YiYang, WenyunZheng*. Designing and constructing a phage display synthesized single domain antibodies library based on camel VHH frame for  screening and identifying humanized TNF-α-specific nanobody，Biomedicine & Pharmacotherapy, 2021, DOI: 10.1016/j.biopha.2021.111328

10. Zhangting Zhao, Xingyuan Ma, Ruihuan Zhang, Fabiao Hu, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang^?, Wenyun Zheng*. A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope 2 self-replication DNA vaccine and its preliminary immune evaluation in 3 experimental animals. Nanomedicine: Nanotechnology, Biology, and Medicine. 2021, (35): 102338.

11. Lingke Liu, Xiaoxiao Chen, Ruilin Gao, Kejian Wang, Wenyun Zheng^?, Haipeng Liu^?. A cytokine receptor domeless promotes white spot syndrome virus infection via JAK/STAT signaling pathway in red claw crayfish Cherax quadricarinatus. Developmental and Comparative Immunology, 2020, 111: 103749.

12. Fabiao Hu, Ruihuan Zhang, Wei Guo, Ting Yan, Xiujuan He, Fengzhi Hu, Fuzheng Ren, Xingyuan Ma*, Jiandu Lei, Wenyun Zheng*. PEGylated-PLGA Nanoparticles Coated With pH Responsive Tannic acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer，Molecular Pharmaceutics. 2021, 18(6):2161-2173.

13. Fabiao Hu,Ting Yan, Wei Guo, Qiuli Liu, Myong Hun Han, Chang Liu,Yuping Liu, Wenyun Zheng*, Fang You*, Yi Yang, Wenliang Zhang and Xingyuan Ma*. Multiple targeting strategies achieve novel protein drug deliver into cancer cells to proapoptosis lung cancer cell by precisely inhibiting surviving. Nanoscale. 2020, 12,10623-10638.

14. Wenpeng Wang#, Wenyun Zheng#, Fengzhi Hu, Xiujuan He, Dong Wu, Wenliang Zhang, Haipeng Liu，and Xingyuan Ma*. Enhanced Biosynthesis Performance of Heterologous Proteins in CHO-K1 Cells Using CRISPR-Cas9. ACS Synth. Biol. 2018, 7, 1259-1268.

15. Chen XX, Li YY, Chang XJ, Xie XL, Liang YT, Wang KJ, Zheng WY*, Liu HP*. A CqFerritin protein inhibits white spot syndrome virus infection via regulating iron ions in red claw crayfish Cherax quadricarinatus. Dev Comp Immunol.2018; 82:104-112.  

16. Fabiao Hu, Daxia Pan, Wenyun Zheng*, Xiujuan He, Fuzheng Ren, Yiming Lu, Xingyuan Ma.Elucidating respective functions of two domains BIR and CHelix of human IAP survivin for precise targeted regulating mitotic cycleapoptosis and autophagy of cancer cells. Oncotarget. 2017,8(69):113687-113700.

17. Di Liu, Fabiao Hu, Wenpeng Wang, Dong Wu, Xiujuan He, Wenyun Zheng*, Haipeng Liu*, Xingyuan Ma*. Elucidating bottlenecks of the efficient preparation of an AB5hexamer mucosal adjuvant protein LTm by genetic engineering. Journal of Microbiology and Biotechnology. 2017, 27(8):1461-147.

18. Xingyuan Ma, Yi Zhang, Yanyan Kang, Linfeng Li, Wenyun Zheng*. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells (BCSCs) by down-regulating the expression of Cyclin D1. Biomedicine & Pharmacotherapy, 2016, 23(84):373-381

19. Xingyuan Ma, Nanjing Lin, Yanyan Kang, Linfeng Li, Wenyun Zheng*, Screening and identification of highly specific McAbs for discovering novel biomarkers of bone marrow stromal cells, Monoclonal Antibody in immunodiagnosis and immunotherapy, 2016, 35(4): 199-211.

20. Liqun Wang, Yanyan Kang, Wenyun Zheng*, Linfeng Li, Lei Shi, Xingyuan Ma. Effect on apoptosis and cell cycle of recombinant double negative dominant mutation Survivin (T34/117A) in breast cancer cell B-Cap-37. Biomedicine & Pharmacotherapy, 2014, 68(3): 277–284

21. Nanjing Lin^#, Wenyun Zheng^#, Linfeng Li, Hui Liu, Tianwen Wang, Ping Wang, Xingyuan Ma*. A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells.Targeted Oncology. 2014, 9(2): 163-170.

22. Wenyun Zheng, Wenyao Zhang, Wei Hu, and Yi Yang，Exploring the Smallest Active Fragment of HsQSOX1b and Discovery of a Highly Efficient Oxidative Engine,PLoS One. 2012,7 (7): e40935. doi:10.1371.

23. Yuxin Xu^#, Wenyun Zheng^#, Tianwen Wang, Ping Wang, Ling Zhu, Xingyuan Ma*. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin. Biomedicine & Pharmacotherapy, 2012, 66(5): 368-372.

24. Wenyun Zheng, Yanyan Chu, Qin Yin, Charles Yang, Wenyao Zhang, Yun Tang, Yi Yang. Crucial effect of the First CXXC Motif of Human QSOX 1b on the Activity to different substrates. Journal of Biochemistry. 2011, 149(3):293-300.

25. Wenyun Zheng, Yanyan Kang, Linfeng Li, Yuxin Xu, Xingyuan Ma, Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discoveries & Therapeutics. 2011, 5(6):293-2989.  

授權(quán)專利：

1.  發(fā)明名稱：抗PD-L1納米抗體及其應(yīng)用，專利授權(quán)號：ZL202010808068.8

2.  發(fā)明名稱：基于鯊魚抗體可變區(qū)V-NAR的噬菌體文庫及其構(gòu)建方法,專利授權(quán)號：ZL202010808119.7

3.  發(fā)明名稱：靶向TNF-α的人源化納米抗體及其制備和用途，專利授權(quán)號：ZL202011297844.9

4.  發(fā)明名稱：負(fù)載Survivin雙抑制劑的鐵蛋白納米顆粒及其制備方法和應(yīng)用, 專利授權(quán)號: ZL202010397566.8

5.  發(fā)明名稱：抑制WSSV增殖的半胱天冬氨酸酶基因Cq-caspase及其蛋白抗病毒活性應(yīng)用，專利授權(quán)號:  ZL201811089877.7

6.  發(fā)明名稱：納米抗體靶向性泛素化降解細(xì)胞內(nèi)源性Survivin組合物及其應(yīng)用，專利授權(quán)號：ZL202010421352.X

7. 發(fā)明名稱: 一種腫瘤化療藥物的蛋白增敏劑，專利授權(quán)號： ZL201010608978.8

8.  發(fā)明名稱：一種增強多肽藥物從細(xì)胞內(nèi)體逃離的蛋白載藥系統(tǒng)及其應(yīng)用；專利授權(quán)號：ZL201310178357.4

9. 發(fā)明名稱：一種內(nèi)含肽介導(dǎo)的類彈性蛋白純化重組蛋白的方法，專利授權(quán)號：ZL201110236772.1

10. 發(fā)明名稱：來自LT亞基的細(xì)胞穿膜肽LTA2作為細(xì)胞內(nèi)藥物運輸載體的應(yīng)用，專利授權(quán)號：ZL201410785006.4

11.  發(fā)明名稱：一種基于組合自剪切與蛋白支架的生物活性小肽制備方法，專利授權(quán)號：ZL201611243905.7

誠邀您的訪問和加盟:合作共贏！